Literature DB >> 22682748

Spatially resolved regression analysis of pre-treatment FDG, FLT and Cu-ATSM PET from post-treatment FDG PET: an exploratory study.

Stephen R Bowen1, Richard J Chappell, Søren M Bentzen, Michael A Deveau, Lisa J Forrest, Robert Jeraj.   

Abstract

PURPOSE: To quantify associations between pre-radiotherapy and post-radiotherapy PET parameters via spatially resolved regression.
MATERIALS AND METHODS: Ten canine sinonasal cancer patients underwent PET/CT scans of [(18)F]FDG (FDG(pre)), [(18)F]FLT (FLT(pre)), and [(61)Cu]Cu-ATSM (Cu-ATSM(pre)). Following radiotherapy regimens of 50 Gy in 10 fractions, veterinary patients underwent FDG PET/CT scans at 3 months (FDG(post)). Regression of standardized uptake values in baseline FDG(pre), FLT(pre) and Cu-ATSM(pre) tumour voxels to those in FDG(post) images was performed for linear, log-linear, generalized-linear and mixed-fit linear models. Goodness-of-fit in regression coefficients was assessed by R(2). Hypothesis testing of coefficients over the patient population was performed.
RESULTS: Multivariate linear model fits of FDG(pre) to FDG(post) were significantly positive over the population (FDG(post) ~ 0.17 · FDG(pre), p = 0.03), and classified slopes of RECIST non-responders and responders to be different (0.37 vs. 0.07, p = 0.01). Generalized-linear model fits related FDG(pre) to FDG(post) by a linear power law (FDG(post) ~ FDG(pre)(0.93),p<0.001). Univariate mixture model fits of FDG(pre) improved R(2) from 0.17 to 0.52. Neither baseline FLT PET nor Cu-ATSM PET uptake contributed statistically significant multivariate regression coefficients.
CONCLUSIONS: Spatially resolved regression analysis indicates that pre-treatment FDG PET uptake is most strongly associated with three-month post-treatment FDG PET uptake in this patient population, though associations are histopathology-dependent.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22682748      PMCID: PMC3489967          DOI: 10.1016/j.radonc.2012.05.002

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  51 in total

1.  On biologically conformal boost dose optimization.

Authors:  M Alber; F Paulsen; S M Eschmann; H J Machulla
Journal:  Phys Med Biol       Date:  2003-01-21       Impact factor: 3.609

Review 2.  Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality.

Authors:  C C Ling; J Humm; S Larson; H Amols; Z Fuks; S Leibel; J A Koutcher
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-06-01       Impact factor: 7.038

3.  Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC).

Authors:  Agathe Edet-Sanson; Bernard Dubray; Kaya Doyeux; Adeline Back; Sebastien Hapdey; Romain Modzelewski; Pierre Bohn; Isabelle Gardin; Pierre Vera
Journal:  Radiother Oncol       Date:  2011-08-30       Impact factor: 6.280

4.  The maximum standardized uptake value (SUVmax) on FDG-PET is a strong predictor of local recurrence for localized non-small-cell lung cancer after stereotactic body radiotherapy (SBRT).

Authors:  Atsuya Takeda; Noriko Yokosuka; Toshio Ohashi; Etsuo Kunieda; Hirofumi Fujii; Yousuke Aoki; Naoko Sanuki; Naoyoshi Koike; Yukihiko Ozawa
Journal:  Radiother Oncol       Date:  2011-08-31       Impact factor: 6.280

5.  Multimodality functional imaging of spontaneous canine tumors using 64Cu-ATSM and 18FDG PET/CT and dynamic contrast enhanced perfusion CT.

Authors:  Anders E Hansen; Annemarie T Kristensen; Ian Law; Fintan J McEvoy; Andreas Kjær; Svend A Engelholm
Journal:  Radiother Oncol       Date:  2011-11-24       Impact factor: 6.280

6.  Hypoxia imaging with [F-18] FMISO-PET in head and neck cancer: potential for guiding intensity modulated radiation therapy in overcoming hypoxia-induced treatment resistance.

Authors:  Kristi Hendrickson; Mark Phillips; Wade Smith; Lanell Peterson; Kenneth Krohn; Joseph Rajendran
Journal:  Radiother Oncol       Date:  2011-08-27       Impact factor: 6.280

7.  Combined PET/CT image characteristics for radiotherapy tumor response in lung cancer.

Authors:  Manushka Vaidya; Kimberly M Creach; Jennifer Frye; Farrokh Dehdashti; Jeffrey D Bradley; Issam El Naqa
Journal:  Radiother Oncol       Date:  2011-11-16       Impact factor: 6.280

8.  NADPH-cytochrome P-450 reductase in the plasma membrane modulates the activation of hypoxia-inducible factor 1.

Authors:  Mayuko Osada; Susumu Imaoka; Toshikado Sugimoto; Toyoko Hiroi; Yoshihiko Funae
Journal:  J Biol Chem       Date:  2002-04-23       Impact factor: 5.157

9.  Retention mechanism of hypoxia selective nuclear imaging/radiotherapeutic agent cu-diacetyl-bis(N4-methylthiosemicarbazone) (Cu-ATSM) in tumor cells.

Authors:  A Obata; E Yoshimi; A Waki; J S Lewis; N Oyama; M J Welch; H Saji; Y Yonekura; Y Fujibayashi
Journal:  Ann Nucl Med       Date:  2001-12       Impact factor: 2.668

Review 10.  Biologically optimized 3-dimensional in vivo predictive assay-based radiation therapy using positron emission tomography-computerized tomography imaging.

Authors:  Anders Brahme
Journal:  Acta Oncol       Date:  2003       Impact factor: 4.089

View more
  7 in total

1.  Differential hepatic avoidance radiation therapy: Proof of concept in hepatocellular carcinoma patients.

Authors:  Stephen R Bowen; Jatinder Saini; Tobias R Chapman; Robert S Miyaoka; Paul E Kinahan; George A Sandison; Tony Wong; Hubert J Vesselle; Matthew J Nyflot; Smith Apisarnthanarax
Journal:  Radiother Oncol       Date:  2015-04-28       Impact factor: 6.280

2.  Voxel Forecast for Precision Oncology: Predicting Spatially Variant and Multiscale Cancer Therapy Response on Longitudinal Quantitative Molecular Imaging.

Authors:  Stephen R Bowen; Daniel S Hippe; W Art Chaovalitwongse; Chunyan Duan; Phawis Thammasorn; Xiao Liu; Robert S Miyaoka; Hubert J Vesselle; Paul E Kinahan; Ramesh Rengan; Jing Zeng
Journal:  Clin Cancer Res       Date:  2019-05-29       Impact factor: 12.531

3.  Heterogeneity in intratumor correlations of 18F-FDG, 18F-FLT, and 61Cu-ATSM PET in canine sinonasal tumors.

Authors:  Tyler J Bradshaw; Stephen R Bowen; Ngoneh Jallow; Lisa J Forrest; Robert Jeraj
Journal:  J Nucl Med       Date:  2013-09-16       Impact factor: 10.057

4.  Use of Molecular Imaging Markers of Glycolysis, Hypoxia and Proliferation ((18)F-FDG, (64)Cu-ATSM and (18)F-FLT) in a Dog with Fibrosarcoma: The Importance of Individualized Treatment Planning and Monitoring.

Authors:  Kamilla Westarp Zornhagen; Malene M Clausen; Anders E Hansen; Ian Law; Fintan J McEvoy; Svend A Engelholm; Andreas Kjær; Annemarie T Kristensen
Journal:  Diagnostics (Basel)       Date:  2015-09-11

Review 5.  The Importance of the Tumor Microenvironment and Hypoxia in Delivering a Precision Medicine Approach to Veterinary Oncology.

Authors:  Mark Gray; James Meehan; Arran K Turnbull; Carlos Martínez-Pérez; Charlene Kay; Lisa Y Pang; David J Argyle
Journal:  Front Vet Sci       Date:  2020-11-12

6.  Validation of nonrigid registration in pretreatment and follow-up PET/CT scans for quantification of tumor residue in lung cancer patients.

Authors:  Jolanda Spijkerman; Davide Fontanarosa; Marco Das; Wouter Van Elmpt
Journal:  J Appl Clin Med Phys       Date:  2014-07-08       Impact factor: 2.102

7.  Advanced Cancer Imaging Applied in the Comparative Setting.

Authors:  David M Vail; Amy K LeBlanc; Robert Jeraj
Journal:  Front Oncol       Date:  2020-02-07       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.